Paralel Advisors LLC Acquires Shares of 38,091 Bristol Myers Squibb Company $BMY

Paralel Advisors LLC acquired a new position in shares of Bristol Myers Squibb Company (NYSE:BMY) in the second quarter, according to its most recent disclosure with the SEC. The firm acquired 38,091 shares of the biopharmaceutical company’s stock, valued at approximately $2,195,000.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Ameritas Advisory Services LLC increased its holdings in shares of Bristol Myers Squibb by 52.7% in the second quarter. Ameritas Advisory Services LLC now owns 14,839 shares of the biopharmaceutical company’s stock valued at $855,000 after purchasing an additional 5,121 shares during the period. Wedmont Private Capital lifted its holdings in shares of Bristol Myers Squibb by 12.1% during the second quarter. Wedmont Private Capital now owns 19,243 shares of the biopharmaceutical company’s stock worth $1,108,000 after purchasing an additional 2,073 shares during the period. Kintra Wealth LLC lifted its holdings in shares of Bristol Myers Squibb by 28.9% during the second quarter. Kintra Wealth LLC now owns 6,821 shares of the biopharmaceutical company’s stock worth $393,000 after purchasing an additional 1,529 shares during the period. Nilsine Partners LLC grew its position in Bristol Myers Squibb by 4.7% in the 2nd quarter. Nilsine Partners LLC now owns 4,483 shares of the biopharmaceutical company’s stock valued at $258,000 after buying an additional 201 shares during the last quarter. Finally, Saudi Central Bank grew its position in Bristol Myers Squibb by 90.2% in the 2nd quarter. Saudi Central Bank now owns 142,922 shares of the biopharmaceutical company’s stock valued at $8,235,000 after buying an additional 67,780 shares during the last quarter. 76.41% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In related news, SVP Phil M. Holzer sold 500 shares of the stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total value of $33,750.00. Following the sale, the senior vice president directly owned 16,862 shares of the company’s stock, valued at approximately $1,138,185. This represents a 2.88% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.05% of the stock is owned by company insiders.

Bristol Myers Squibb Stock Up 0.0%

BMY stock opened at $66.85 on Monday. The company has a current ratio of 1.53, a quick ratio of 1.38 and a debt-to-equity ratio of 1.89. The company’s 50-day moving average price is $62.92 and its 200 day moving average price is $59.92. Bristol Myers Squibb Company has a 52 week low of $42.52 and a 52 week high of $68.64. The company has a market cap of $136.56 billion, a P/E ratio of 14.72, a P/E/G ratio of 0.32 and a beta of 0.23.

Bristol Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.60 by $0.44. The company had revenue of $12.97 billion during the quarter, compared to analysts’ expectations of $11.74 billion. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. The firm’s quarterly revenue was up 5.7% compared to the same quarter last year. During the same period last year, the company posted $1.46 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. On average, research analysts expect that Bristol Myers Squibb Company will post 6.95 earnings per share for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, August 3rd. Stockholders of record on Thursday, July 2nd were given a $0.63 dividend. The ex-dividend date was Thursday, July 2nd. This represents a $2.52 dividend on an annualized basis and a dividend yield of 3.8%. Bristol Myers Squibb’s dividend payout ratio (DPR) is currently 55.51%.

Key Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers Squibb announced a Phase 2 trial evaluating a therapy in depression, expanding its pipeline into a large potential market. Positive clinical progress could provide a new growth opportunity if the treatment demonstrates efficacy and safety. Bristol-Myers Squibb Moves Into Depression Market With New Phase 2 Trial
• Positive Sentiment: Analysts and financial commentators continue to highlight BMY’s relatively low valuation, roughly 3.7% forward dividend yield, strong margins and growth products that are offsetting declines in older medicines. These factors support the stock’s defensive and income-oriented appeal. Bristol Myers Squibb: Still Cheap, Despite What The Chart Says
• Neutral Sentiment: Technical indicators have reportedly turned bullish, while RBC Capital maintained a Hold rating, indicating that analysts see some upside but remain cautious about the company’s outlook. Bristol-Myers Squibb Stock: Is BMY Outperforming the Healthcare Sector?
• Negative Sentiment: Bristol Myers Squibb paused enrollment in its zola-cel autoimmune cell-therapy trials after safety surveillance identified inflammatory side effects. Reports that the pause involved serious safety concerns raised questions about the program’s risk profile, development timeline and broader cell-therapy strategy. What Does Bristol Myers Squibb Trial Pause Mean For Its Pipeline?
• Negative Sentiment: The wider healthcare sector traded lower, adding industry-level pressure to BMY. Investors also continue to monitor legacy-drug declines, including Opdivo, and future Eliquis patent-expiry risks. Sector Update: Healthcare Stocks Decline Friday Afternoon

Analysts Set New Price Targets

BMY has been the subject of a number of analyst reports. Raymond James Financial started coverage on shares of Bristol Myers Squibb in a research report on Wednesday, August 5th. They set a “strong-buy” rating for the company. BMO Capital Markets reaffirmed a “market perform” rating on shares of Bristol Myers Squibb in a report on Monday, July 27th. JPMorgan Chase & Co. increased their price target on shares of Bristol Myers Squibb from $67.00 to $73.00 and gave the stock an “overweight” rating in a report on Friday, July 31st. Piper Sandler assumed coverage on shares of Bristol Myers Squibb in a research report on Wednesday, August 5th. They issued an “overweight” rating for the company. Finally, UBS Group cut Bristol Myers Squibb from a “buy” rating to a “neutral” rating in a research report on Wednesday, August 5th. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $66.06.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late?stage pipeline reflect a strong emphasis on cancer and immune?mediated conditions.